BMC Clinical Pharmacology

Table 4 Treatment persistence

From: Use, tolerability and compliance of spironolactone in the treatment of heart failure

	Persistence
	3 months	6 months	12 months
ACE	83.6%	75.3%	64.5%
ARB	84.8%	77.5%	66.3%
β-blockers	86.3%	80.0%	70.4%
Spironolactone	76.3%*	65.3%*	50.7%*

* Spironolactone versus ACE, ARB and β-blockers: p < 0.001 (Pearson's chi square test)

Back to article page